Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering
Advanced Healthcare Materials · 2023-07 · 12 (17)
DOI: 10.1002/adhm.202202271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 15.03.2023. Verfasst von Angela Bonato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences and Technology, ETH Zürich, Zürich, 8093, Switzerland. Hauptthemen laut MEDLINE: Tissue Engineering, Cartilage, Articular. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Suomen Kulttuurirahasto.
Abstract (Originalsprache)
Articular cartilage defects caused by traumatic injury rarely heal spontaneously and predispose into post‐traumatic osteoarthritis. In the current autologous cell‐based treatments the regenerative process is often hampered by the poor regenerative capacity of adult cells and the inflammatory state of the injured joint. The lack of ideal treatment options for cartilage injuries motivated the authors to tissue engineer a cartilage tissue which would be more resistant to inflammation. A clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 knockout of TGF‐ β ‐activated kinase 1 ( TAK1 ) gene in polydactyly chondrocytes provides multivalent protection against the signals that activate the pro‐inflammatory and catabolic NF‐ κ B pathway. The TAK1 ‐KO chondrocytes encapsulate into a hyaluronan hydrogel deposit copious cartilage extracellular matrix proteins and facilitate integration onto native cartilage, even under proinflammatory conditions. Furthermore, when implanted in vivo, compared to WT fewer pro‐inflammatory M1 macrophages invade the cartilage, likely due to the lower levels of cytokines secreted by the TAK1 ‐KO polydactyly chondrocytes. The engineered cartilage thus represents a new paradigm‐shift for the creation of more potent and functional tissues for use in regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences and Technology, ETH Zürich, Zürich, 8093, Switzerland.
- Orton Orthopedic Hospital Helsinki, Helsinki, 00280, Finland.
- Division of Hand Surgery, University Children's Hospital, Zürich, 8032, Switzerland.
- Department of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, 00014, Finland.
- Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland.
ORCID-Profile: Angela Bonato, Philipp Fisch, Mikko Manninen, Goncalo Barreto, Marcy Zenobi-Wong
Förderung
- Suomen Kulttuurirahasto
Zitieren
APA
Bonato, A., Fisch, P., Ponta, S., Fercher, D., Manninen, M., Weber, D., Eklund, K. K., Barreto, G., & Zenobi-Wong, M. (2023). Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering. Advanced Healthcare Materials, 12(17). https://doi.org/10.1002/adhm.202202271
Vancouver
Bonato A, Fisch P, Ponta S, Fercher D, Manninen M, Weber D, et al. Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering. Advanced Healthcare Materials. 2023;12(17). doi:10.1002/adhm.202202271
BibTeX
@article{Bonato2023,
author = {Bonato, Angela and Fisch, Philipp and Ponta, Simone and Fercher, David and Manninen, Mikko and Weber, Daniel and Eklund, Kari K and Barreto, Goncalo and Zenobi-Wong, Marcy},
title = {Engineering Inflammation‐Resistant Cartilage: Bridging Gene Therapy and Tissue Engineering},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {17},
doi = {10.1002/adhm.202202271}
}
EUVIMED